SCHEMBL1660429

SCHEMBL1660429

COc1ccc(C=CC(=O)OCC(O)COC(=O)C=Cc2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 2/20 0.60
KDM4E B2RXH2 4/20 0.59
HPGD P15428 2/20 0.59
ALDH1A1 P00352 3/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 1/20 0.57
TUBB4A P04350 1/20 0.57
TUBB P07437 1/20 0.57
TUBA3C P0DPH7 1/20 0.57
TUBA1B P68363 1/20 0.57
TUBA4A P68366 1/20 0.57
TUBB4B P68371 1/20 0.57
TUBB3 Q13509 1/20 0.57
TUBB2A Q13885 1/20 0.57
TUBB8 Q3ZCM7 1/20 0.57
TUBA3E Q6PEY2 1/20 0.57
TUBA1A Q71U36 1/20 0.57
TUBA1C Q9BQE3 1/20 0.57
TUBB6 Q9BUF5 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1660425 1.00 TNFRSF1A (0.60) TNFRSF1AKDM4EHPGDALDH1A1KMT2A
SCHEMBL1660427 1.00 TNFRSF1A (0.60) TNFRSF1AKDM4EHPGDALDH1A1KMT2A
SCHEMBL12793457 0.91 TTR (0.57) KDM4EHPGDALDH1A1KMT2AMEN1
SCHEMBL12731782 0.91 MAOB (0.66) KDM4EHPGDALDH1A1KMT2AMEN1
SCHEMBL1660732 0.90 MET (0.57) KDM4EHPGDALDH1A1KMT2AMEN1
SCHEMBL11903912 0.90 TTR (0.65) TNFRSF1AKDM4EHPGDALDH1A1KMT2A
SCHEMBL15169491 0.90 FDPS (0.59) KDM4EHPGDALDH1A1KMT2AMEN1
SCHEMBL1660735 0.90 MET (0.57) KDM4EHPGDALDH1A1KMT2AMEN1
SCHEMBL11903909 0.90 TTR (0.65) TNFRSF1AKDM4EHPGDALDH1A1KMT2A
SCHEMBL1660737 0.90 MET (0.57) KDM4EHPGDALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486026-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MacGregor, Alexander (CA) 2012-08-15 EP claimed
US-20110086912-A1 Derivatives of Propane Diyl Dicinnamate MACGREGOR ALEXANDER 2011-04-14 US claimed
WO-2011041907-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MACGREGOR ALEXANDER (CA) 2011-04-14 WO claimed
US-10052301-B2 Derivatives of propane diyl dicinnamate ORX PHARMACEUTICAL CORPORATION (CA) 2018-08-21 US disclosed
US-20150246014-A1 Derivatives of Propane Diyl Dicinnamate ORX PHARMACEUTICAL CORPORATION (CA) 2015-09-03 US disclosed
US-9061993-B2 Derivatives of propane diyl dicinnamate Toronto Institute of Pharmaceutical Technology (CA) 2015-06-23 US disclosed
EP-2486026-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MacGregor, Alexander (CA) 2012-08-15 EP disclosed
US-20110086912-A1 Derivatives of Propane Diyl Dicinnamate MACGREGOR ALEXANDER 2011-04-14 US disclosed
WO-2011041907-A1 DERIVATIVES OF DI(PHENYLPROPANOID) GLYCEROL FOR THE TREATMENT OF CANCER MACGREGOR ALEXANDER (CA) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246014-A1 Derivatives of Propane Diyl Dicinnamate H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DECR2, DECR1 TNFRSF1A 2598/4885KDM4E 1830/4885HPGD 363/4885
US-10052301-B2 Derivatives of propane diyl dicinnamate H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DECR2, DECR1 TNFRSF1A 2598/4885KDM4E 1830/4885HPGD 363/4885
US-20110086912-A1 Derivatives of Propane Diyl Dicinnamate H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DECR2, DECR1 TNFRSF1A 2581/4885KDM4E 1786/4885HPGD 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.